N/A N=6,011

European Regulatory Science on Tobacco: Policy Implementation to Reduce Lung Diseases (EUREST-PLUS)

Tobacco Dependence

Bottom Line

View on ClinicalTrials.gov: NCT02773836 ↗

Enrolled (actual)

6,011

Serious AEs

0.0%

Results posted

Jun 2019

Primary outcome: Primary: Number of Participants Who Think About the Harm of Smoking — 67; 272; 192; 194 Participants

Study Design & Population

Study type: Observational
Phase: N/A
Interventions: Questionnaire (Other)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: European Network For Smoking and Tobacco Prevention
Primary completion: Sep 2016

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Participants Who Think About the Harm of Smoking	109; 328; 229; 147; 288; 274	—
PRIMARY Number of Participants Whose First Cigarette After Waking is 30 Mins or Less	207; 118; 254; 179; 256; 207	—
PRIMARY Number of Participants Who Think About How Much They Enjoy Smoking by Frequency	79; 171; 275; 294; 189; 261	—
PRIMARY Number of Participants Who Have Ever Tried to Quit Smoking	367; 505; 553; 517; 431; 475	—
PRIMARY Number of Participants Who Plan to Quit Smoking	11; 26; 46; 39; 19; 12	—
PRIMARY Number of Participants Who Think About the Harm of Smoking	109; 328; 229; 147; 288; 274	—
PRIMARY Number of Participants Whose First Cigarette After Waking is 30 Mins or Less	207; 118; 254; 179; 256; 207	—
PRIMARY Number of Participants Who Have Ever Tried to Quit Smoking	367; 505; 553; 517; 431; 475	—
PRIMARY Number of Participants Who Plan to Quit Smoking	11; 26; 46; 39; 19; 12	—
SECONDARY Number of Participants Who Think About The Money They Spend on Smoking	84; 260; 167; 123; 196; 182	—
SECONDARY Number of Participants Who Think About the Harm Their Smoking Might be Doing to Other People	114; 367; 225; 157; 307; 277	—
SECONDARY Number of Participants Who Think About The Money They Spend on Smoking	84; 260; 167; 123; 196; 182	—
SECONDARY Number of Participants Who Think About the Harm Their Smoking Might be Doing to Other People	114; 367; 225; 157; 307; 277	—

Summary

The main objective of EUREST-PLUS is to monitor and evaluate the impact of the Tobacco Products Directive (TPD) within the context of FCTC ratification at an EU level. The investigators specific objectives, within WorkPackage 2 and Workpackage 3 are: To evaluate the psychosocial and behavioral impact of TPD implementation and FCTC implementation, through the creation of a cohort study of adult smokers in 6 European Member States (EU MS), Germany, Greece, Hungary, Poland, Romania, Spain; (total n=6000) in a pre- vs. post-TPD study design. EUREST-PLUS is funded through the European Union's Horizon 2020 research and innovation programme under grant agreement No 681109

Eligibility Criteria

Inclusion Criteria

Must be 18 years of age or older.
Must smoke at least monthly.
Must have smoked 100 cigarettes in their lifetime.
Must live in the household visited

Exclusion Criteria

Inability to complete the questionnaire due to health/mental incapability.
Unable to provide consent to participate.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02773836). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.